Table 2.
Clinical characteristics of the pregnancies.
| At Conception | OCR Infusions | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mother | Newborn | Age | Duration of disease (weeks) | No. of cycles of OCR infusions | Before conception (weeks) | During pregnancy (weeks) | Postpartum (weeks) | Duration of treatment interruption (weeks) | Pregnancy complications | B-cell repopulation during pregnancy | Relapse |
| M1 | TOP * | 32 | 120 | 1 | 13 | No | 2 | No | Fetal anomalies, triploidy | No | No |
| NB1 | 33 | 132 | 2 | 18 | No | 48 | 105 | No | No | No | |
| M2 | NB2 | 38 | 132 | 1 | 18 | 6 | 21 | 57 | No | No | No |
| M3 | NB3 | 34 | 156 | 2 | 22 | 9 | 31 | 64 | No | No | No |
| M4 | NB4 | 34 | 12 | 1 | 2 | No | 30 | 72 | No | No | No |
| NB5 | 36 | 48 | 3 | 17 | No | 9 | 66 | No | No | No | |
| M5 | NB6 | 40 | 120 | 2 | 11 | No | 7 | 56 | Breech presentation | No | No |
| M6 | NB7 | 39 | 48 | 1 | 24 | No | 24 | 88 | No | No | No |
| M7 | NB8 | 30 | 48 | 2 | 8 | No | 1 | 46 | Placental insufficiency, oligohydramnios, breech presentation | Yes (At 35w of gestation) | No |
| M8 | NB9 | 32 | 12 | 2 | 21 | No † | Switched to NTZ during pregnancy | Switched to NTZ during pregnancy | No | Yes (At 2w of gestation) | No |
| M9 | NB10 | 35 | 12 | 2 | 18 | No | 29 | 85 | GDM, primary PPH | No | No |
| M10 | NB11 | 33 | 1 | 1 (only a single dose of 300mg of OCR) | No | 2 ¶ | 4 | 40 | No | No | No |
| M11 | NB12 | 37 | 36 | 4 | 13 | No | 8 | 61 | No | No | No |
| M12 | NB13 | 34 | 36 | 2 | 0.4 | No | 1 | 41 | No | No | No |
Legend: OCR: ocrelizumab, w: weeks, M: male, F: female, SVD: spontaneous vaginal delivery, LSCS: lower segment Caesarean Section, GDM: gestational diabetes, PPH: postpartum haemorrhage, NTZ: natalizumab, TOP: termination of pregnancy.
* Fetal alobar holoprosencephaly and nuchal thickening, facial abnormalities and exomphalos, resulting in termination of pregnancy with cytogenetics confirming triploidy 69 XXY which occurs de novo.
† Mother received Natalizumab infusions throughout pregnancy as a bridging therapy in view of B cells repopulation during early stage of pregnancy.
¶ Only received a single 300mg dose of IV ocrelizumab. Was due for the second 300mg dose of ocrelizumab but fell pregnant before the scheduled infusion.